Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review - PubMed (original) (raw)
Review
. 2007 Mar 21;297(11):1233-40.
doi: 10.1001/jama.297.11.1233.
Affiliations
- PMID: 17374817
- DOI: 10.1001/jama.297.11.1233
Review
Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review
Harriette G C Van Spall et al. JAMA. 2007.
Abstract
Context: Selective eligibility criteria of randomized controlled trials (RCTs) are vital to trial feasibility and internal validity. However, the exclusion of certain patient populations may lead to impaired generalizability of results.
Objective: To determine the nature and extent of exclusion criteria among RCTs published in major medical journals and the contribution of exclusion criteria to the representation of certain patient populations.
Data sources and study selection: The MEDLINE database was searched for RCTs published between 1994 and 2006 in certain general medical journals with a high impact factor. Of 4827 articles, 283 were selected using a series technique.
Data extraction: Trial characteristics and the details regarding exclusions were extracted independently. All exclusion criteria were graded independently and in duplicate as either strongly justified, potentially justified, or poorly justified according to previously developed and pilot-tested guidelines.
Data synthesis: Common medical conditions formed the basis for exclusion in 81.3% of trials. Patients were excluded due to age in 72.1% of all trials (60.1% in pediatric populations and 38.5% in older adults). Individuals receiving commonly prescribed medications were excluded in 54.1% of trials. Conditions related to female sex were grounds for exclusion in 39.2% of trials. Of all exclusion criteria, only 47.2% were graded as strongly justified in the context of the specific RCT. Exclusion criteria were not reported in 12.0% of trials. Multivariable analyses revealed independent associations between the total number of exclusion criteria and drug intervention trials (risk ratio, 1.35; 95% confidence interval, 1.11-1.65; P = .003) and between the total number of exclusion criteria and multicenter trials (risk ratio, 1.26; 95% confidence interval, 1.06-1.52; P = .009). Industry-sponsored trials were more likely to exclude individuals due to concomitant medication use, medical comorbidities, and age. Drug intervention trials were more likely to exclude individuals due to concomitant medication use, medical comorbidities, female sex, and socioeconomic status. Among such trials, justification for exclusions related to concomitant medication use and comorbidities were more likely to be poorly justified.
Conclusions: The RCTs published in major medical journals do not always clearly report exclusion criteria. Women, children, the elderly, and those with common medical conditions are frequently excluded from RCTs. Trials with multiple centers and those involving drug interventions are most likely to have extensive exclusions. Such exclusions may impair the generalizability of RCT results. These findings highlight a need for careful consideration and transparent reporting and justification of exclusion criteria in clinical trials.
Comment in
- Eligibility criteria of randomized controlled trials.
Costantino G, Ceriani E, Rusconi AM, Montano N. Costantino G, et al. JAMA. 2007 Jul 4;298(1):39; author reply 39-40. doi: 10.1001/jama.298.1.39-a. JAMA. 2007. PMID: 17609487 No abstract available.
Similar articles
- Eligibility Criteria of Randomized Clinical Trials in Critical Care Medicine.
Heirali A, Heybati K, Sereeyotin J, Khan F, Yarnell C, Krewulak K, Murthy S, Burns KEA, Fowler R, Fiest K, Mehta S; Canadian Critical Care Trials Group. Heirali A, et al. JAMA Netw Open. 2025 Jan 2;8(1):e2454944. doi: 10.1001/jamanetworkopen.2024.54944. JAMA Netw Open. 2025. PMID: 39821399 Free PMC article. - The future of Cochrane Neonatal.
Soll RF, Ovelman C, McGuire W. Soll RF, et al. Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834 - Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England.
Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Tan YY, et al. Lancet Healthy Longev. 2022 Oct;3(10):e674-e689. doi: 10.1016/S2666-7568(22)00186-6. Epub 2022 Sep 20. Lancet Healthy Longev. 2022. PMID: 36150402 - Comparison of registered and published primary outcomes in randomized controlled trials.
Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Mathieu S, et al. JAMA. 2009 Sep 2;302(9):977-84. doi: 10.1001/jama.2009.1242. JAMA. 2009. PMID: 19724045 - Characteristics of Heart Failure Trials Associated With Under-Representation of Women as Lead Authors.
Whitelaw S, Thabane L, Mamas MA, Reza N, Breathett K, Douglas PS, Van Spall HGC. Whitelaw S, et al. J Am Coll Cardiol. 2020 Oct 27;76(17):1919-1930. doi: 10.1016/j.jacc.2020.08.062. J Am Coll Cardiol. 2020. PMID: 33092727 Free PMC article. Review.
Cited by
- Reporting of Sociodemographic Variables in Randomized Clinical Trials, 2014-2020.
Orkin AM, Nicoll G, Persaud N, Pinto AD. Orkin AM, et al. JAMA Netw Open. 2021 Jun 1;4(6):e2110700. doi: 10.1001/jamanetworkopen.2021.10700. JAMA Netw Open. 2021. PMID: 34076703 Free PMC article. - Associations Between Race/Ethnicity, Language, and Enrollment on Cancer Research Studies.
Ezeoke OM, Brooks G, Postow MA, Baxi S, Young Kim S, Narang B, Diamond LC. Ezeoke OM, et al. Oncologist. 2023 Feb 8;28(2):131-138. doi: 10.1093/oncolo/oyac218. Oncologist. 2023. PMID: 36321912 Free PMC article. - Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO. Brioli A, et al. J Cancer Res Clin Oncol. 2020 Mar;146(3):749-759. doi: 10.1007/s00432-019-03101-z. Epub 2019 Dec 2. J Cancer Res Clin Oncol. 2020. PMID: 31788741 Clinical Trial. - Sleep monitoring challenges in patients with neurocognitive disorders: A cross-sectional analysis of missing data from activity trackers.
Ahuja M, Siddhpuria S, Reppas-Rindlisbacher C, Wong E, Gormley J, Lee J, Patterson C. Ahuja M, et al. Health Sci Rep. 2022 Apr 26;5(3):e608. doi: 10.1002/hsr2.608. eCollection 2022 May. Health Sci Rep. 2022. PMID: 35509396 Free PMC article. - Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria's impact on patient count and safety.
Rogers JR, Pavisic J, Ta CN, Liu C, Soroush A, Kuen Cheung Y, Hripcsak G, Weng C. Rogers JR, et al. J Biomed Inform. 2022 Mar;127:104032. doi: 10.1016/j.jbi.2022.104032. Epub 2022 Feb 18. J Biomed Inform. 2022. PMID: 35189334 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources